Page 2460 - Williams Hematology ( PDFDrive )

2431
2430 Index Index 2431

prothrombin activation and, 1854 von Willebrand disease and, 2163, 2172 platelet microparticles and, 1854
structure, 1924 Factor VIII, increased levels prothrombin activation and, 1854
variability in cleavage, 1924, 1955–1956 acquired causes, 2224t Factor X, 1922–1923
Factor V Leiden/factor V G1691A epidemiology, 2222t, 2224 activation, 1854, 1922, 2141
activated protein C resistance and, 1955, etiology and pathogenesis, 1926 characteristics, 1916t, 1922
2222 history, 2222 gene structure and variations, 1922–1923,
arterial thromboembolic disease risk and, myocardial infarction risk and, 2226–2227 1922f, 2141–2142
2226–2227 pathophysiology, 2224 structure, 1854, 1917f, 1922, 2141
clinical features, 2138 venous thromboembolism risk and, 2224, Factor X deficiency, 2141–2142
clinical implications of testing for, 2225–2226, 2225t, 2226t acquired, 2145
2227–2228, 2228t von Willebrand factor and, 2224 clinical features, 2142
fetal loss and, 122 Factor VIII deficiency definition and history, 2141
pathophysiology, 2223, 2223f acquired, 2145, 2183–2186 diagnosis, 1988, 1989f
prevalence, 2138, 2222t, 2223 combined with factor V deficiency, 2134t, gene mutations, 1922, 2135t, 2141–2142
venous thromboembolism risk and, 2222, 2135t, 2136t, 2139–2140 incidence, 1922, 2134t
2225, 2225t, 2226t, 2268 diagnosis, 1988, 1989f therapy, 2136t, 2142
Factor VII, 1920–1921 inherited. See Hemophilia A (classic Factor Xa
activation, 1920, 2140 hemophilia, factor VIII deficiency) activity, 1922
characteristics, 1916t, 2140 Factor VIII inhibitor antibodies, 2124–2126 characteristics, 1918t
gene structure and variations, 1920–1921, diagnosis, 2124–2125 indirect inhibitors. See Danaparoid;
1921f molecular pathology, 2184 Fondaparinux
structure, 1917f, 1920, 2140 prevalence, 2124 in inflammation, 2201
Factor VII deficiency, 2140–2141 risk factors, 2124, 2124t inhibitors, 1922, 1959f, 1960
clinical features, 2141 treatment, 2125–2126, 2125t, 2126t, 2185 protein S and, 1949
definition and history, 2140 Factor VIII replacement structure, 1922
diagnosis, 1988, 1989f for acquired hemophilia A, 2185 thrombin and, 1854, 1940, 1940f
gene mutations, 2135t, 2140–2141 for anti-factor VIII inhibitor antibodies, Factor XI, 1928–1929
incidence, 1920–1921, 2133, 2134t 2125–2126, 2125t acquired antibodies to, 2187
therapy, 2136t, 2141 disease transmission risk with, 2126 activation, 1929, 1949, 2142–2143
Factor VIIa for factor VIII deficiency, 2136t, 2145 characteristics, 1916t, 2142–2143
cofactor and substrates, 1918t for hemophilia A, 2121–2122, 2121t, gene structure and variations, 1928f, 1929
in control of coagulation, 1950, 1959f, 1960 2122t structure, 1927f, 1928–1929, 2142
functions, 1920, 1930 for inherited platelet disorders, 2062 Factor XI deficiency, 2142–2143
structure, 1920, 1920f Factor VIIIa clinical features, 2142
in thrombin generation, 1940, 1940f activation, 1854 definition and history, 2142
Factor VIIa replacement functions, 1926 diagnosis, 1988, 1989f
in cardiac surgery, 2086 in hemophilia, 2114 differential diagnosis, 2121
for factor VII deficiency, 2141 protein S and, 1949 epidemiology, 1929
for hemophilia A, 2125, 2125t, 2185 structure, 1926 gene mutations, 1929, 2135t, 2143
Factor VII-activating protease, 2283 as substrate for activated protein C, 1955 incidence, 2133, 2134t
Factor VIII variability in cleavage, 1955–1956 therapy, 2143
activated protein C and, 1955 Factor IX, 1921–1922 Factor XII, 1929–1930
activation, 1926 activation, 1921 in acute hemolytic transfusion reactions,
antibodies, 2183–2184 characteristics, 1916t, 1921 2374
characteristics, 1916t, 1925 gene structure and variations, 1921–1922, characteristics, 1916t
defined, 2164t 1921f kinin system and, 289
functions, 2183–2184 increased levels, 1922 structure, 1927f, 1929
gene structure and variations, 1926, 1926f structure, 1917f, 1921 Factor XII deficiency, 1988, 2121
in hepatic disease, 2192 Factor IX deficiency. See Hemophilia B Factor XIII
interaction with von Willebrand factor, Factor IX replacement, 2128–2129, 2128t acquired inhibitors to, 2187
2168 Factor IX inhibitor antibodies, 2129 activation, 1934–1935, 1934f, 2144
platelet microparticles and, 1854 Factor IXa characteristics, 1916t, 1933–1934, 2144
structure, 1925–1926 characteristics, 1918t, 1921 crosslinking by, 2153
synthesis, 1925, 1925f factor VIII and, 2184 gene structure and variations, 1935, 1935f,
terminology, 2164t generation, 1921 2144
thrombin and, 1949 in hemophilia, 2114 in platelets, 1848

Kaushansky_index_p2393-2506.indd 2431 9/21/15 3:21 PM